Loading...
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)
OBJECTIVE: Friedreich ataxia (FA) is a progressive genetic neurodegenerative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA. We investigated the safety and efficacy of omaveloxol...
Saved in:
| Published in: | Ann Neurol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley & Sons, Inc.
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7894504/ https://ncbi.nlm.nih.gov/pubmed/33068037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25934 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|